Font Sizes: A A A

Laszlo G. Harsing, Jr.

Present appointment: Senior Advisor

Phone: +36 1 210 29 30/Ext. 56393

Email: harsing

Education and qualification:
1966-1972, Semmelweis University, Faculty of Medicine, Budapest

Present affiliation:
2009- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest

Previous affiliations, Hungary:
1973-1981 Assistant Professor, Department of Pharmacology, Semmelweis University

1981-1986 Senior Research Fellow, Institute of Experimental Medicine, Hungarian Academy of Sciences
1986-1995 Associate Professor Department of Pharmacology,   Postgraduate School of Medicine, Budapest
1992-2000 Vice Director, Institute for Drug Research, Budapest
2000-2008 Vice Director, EGIS Pharmaceuticals Plc, Budapest

Previous affiliations, USA:
1980-1981 National Institute of Mental Health, Washington, DC

1985-1986 Montefiore Hospital, Albert Einstein Colloge of Medicine, New York, NY
1989-1992 Center for Neurochemistry, New York University, Orangeburg, NY
1995-1996 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA

Educational activities:
Lecturing in pharmacology at universities and in postgraduate and PhD schools, graduate and postgraduate levels in Hungarian and English

Scientific Qualifications:
1984, PhD, Regulation of Cholinergic Neurotransmission in the Striatum

1992, DSc, Heterogeneity of Alpha-2 Adrenoceptors
1994, Lecturer in Pharmacology (Dr. Med. Habil.)

Merits and Awards:
Fogarty International Fellowship, National Institutes of Health, 1980,1995

Issekutz Memorial Medal, Hungarian Pharmacological Society, 2000
Order of Merit of Hungary 2018

Research areas:
Pharmacology, academic and industrial

Neuropsychopharmacology, neurotransmitter release and inteactions

Scientific publications and Scientometric data:
Previewed publications: 129

Chapters in textbooks: 39
Abstracts in journals and proceedings: 60
Patents in pharmaceutical drug development: 42
Cumulative impact factor: 237,047
Number of citations: independent 2210, total 2975
Hirsh index: 32

Drug development in clinical phase:
EGIS-11150/S36549, atypical antipsychotic, schizophrenia, US 20050043314 A1, Phase I clinical trial

GYKI-16084, postsynaptic α1 and α2 adrenoceptor antagonist, benign prostate hyperplasia, US 619441 B1, Phase II clinical trial
EGIS-13529/S44819, α5 GABAA receptor inverse agonist, post stroke recovery, US 20120232065 A1, Completed phase II clinical trial

Editorial activities in periodicals:
Neurochemical Research, Associate Editor

Neurochemistry International, Current Medicinal Chemistry, memberships in editorial boards

Membership in professional societies:
Hungarian Pharmacological Society

Hungarian Physiological Society
Society for Neuroscience, USA
European Society for Neuroscience
Australian Neuroscience Society
Society of Neuroscience in Africa (SONA)
International Society for Neurochemistry